Treatment in risperidone-induced amenorrhoea

Bun Hee Lee, Changsu Han, Kye Hyun Kim, Yong Ku Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. To find the optimal changes needed for resolution of amenorrhoea associated with risperidone. Method. Between November 2001 and May 2002, 16 female outpatients who had taken risperidone for more than 3 months voluntarily reported amenorrhoea. Following each report of amenorrhoea, serum prolactin level was measured and treatment changes were undertaken. The menstrual cycles and clinical mental status of each patient were followed for the next 6 months. For nine of the 16 patients, the dose of risperidone was reduced. For the other seven patients, risperidone was switched to olanzapine or quetiapine. Results. Fourteen of 16 patients had hyperprolactinemia. Two patients who had discontinuation of risperidone recovered from amenorrhoea and three of the risperidone-reduction patients resumed their periods. All subjects in the drug-switch patients recovered. The patients who recovered from amenorrhoea at a reduced dosage of risperidone took ≤3 mg/day. Two patients in the risperidone-reduction group dropped out. Conclusion. Stopping risperidone (without starting any other antipsychotic) or switching to a prolactin-sparing antipsychotic is an effective strategy for resolution of amenorrhoea on risperidone, but that dose reduction is rarely effective either because amenorrhoea continues despite lower dose or because relapse of psychosis appears.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalInternational Journal of Psychiatry in Clinical Practice
Volume9
Issue number1
DOIs
Publication statusPublished - 2005 Mar 1

Fingerprint

Risperidone
Amenorrhea
Therapeutics
olanzapine
Prolactin
Antipsychotic Agents
Hyperprolactinemia
Menstrual Cycle
Psychotic Disorders
Outpatients
Recurrence

Keywords

  • Amenorrhea
  • Mood disorder
  • Prolactin
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Treatment in risperidone-induced amenorrhoea. / Lee, Bun Hee; Han, Changsu; Kim, Kye Hyun; Kim, Yong Ku.

In: International Journal of Psychiatry in Clinical Practice, Vol. 9, No. 1, 01.03.2005, p. 29-34.

Research output: Contribution to journalArticle

@article{b6e9eb4f82bf47d3bc7abacbbb1c502a,
title = "Treatment in risperidone-induced amenorrhoea",
abstract = "Objective. To find the optimal changes needed for resolution of amenorrhoea associated with risperidone. Method. Between November 2001 and May 2002, 16 female outpatients who had taken risperidone for more than 3 months voluntarily reported amenorrhoea. Following each report of amenorrhoea, serum prolactin level was measured and treatment changes were undertaken. The menstrual cycles and clinical mental status of each patient were followed for the next 6 months. For nine of the 16 patients, the dose of risperidone was reduced. For the other seven patients, risperidone was switched to olanzapine or quetiapine. Results. Fourteen of 16 patients had hyperprolactinemia. Two patients who had discontinuation of risperidone recovered from amenorrhoea and three of the risperidone-reduction patients resumed their periods. All subjects in the drug-switch patients recovered. The patients who recovered from amenorrhoea at a reduced dosage of risperidone took ≤3 mg/day. Two patients in the risperidone-reduction group dropped out. Conclusion. Stopping risperidone (without starting any other antipsychotic) or switching to a prolactin-sparing antipsychotic is an effective strategy for resolution of amenorrhoea on risperidone, but that dose reduction is rarely effective either because amenorrhoea continues despite lower dose or because relapse of psychosis appears.",
keywords = "Amenorrhea, Mood disorder, Prolactin, Risperidone, Schizophrenia",
author = "Lee, {Bun Hee} and Changsu Han and Kim, {Kye Hyun} and Kim, {Yong Ku}",
year = "2005",
month = "3",
day = "1",
doi = "10.1080/13651500510014747",
language = "English",
volume = "9",
pages = "29--34",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Treatment in risperidone-induced amenorrhoea

AU - Lee, Bun Hee

AU - Han, Changsu

AU - Kim, Kye Hyun

AU - Kim, Yong Ku

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Objective. To find the optimal changes needed for resolution of amenorrhoea associated with risperidone. Method. Between November 2001 and May 2002, 16 female outpatients who had taken risperidone for more than 3 months voluntarily reported amenorrhoea. Following each report of amenorrhoea, serum prolactin level was measured and treatment changes were undertaken. The menstrual cycles and clinical mental status of each patient were followed for the next 6 months. For nine of the 16 patients, the dose of risperidone was reduced. For the other seven patients, risperidone was switched to olanzapine or quetiapine. Results. Fourteen of 16 patients had hyperprolactinemia. Two patients who had discontinuation of risperidone recovered from amenorrhoea and three of the risperidone-reduction patients resumed their periods. All subjects in the drug-switch patients recovered. The patients who recovered from amenorrhoea at a reduced dosage of risperidone took ≤3 mg/day. Two patients in the risperidone-reduction group dropped out. Conclusion. Stopping risperidone (without starting any other antipsychotic) or switching to a prolactin-sparing antipsychotic is an effective strategy for resolution of amenorrhoea on risperidone, but that dose reduction is rarely effective either because amenorrhoea continues despite lower dose or because relapse of psychosis appears.

AB - Objective. To find the optimal changes needed for resolution of amenorrhoea associated with risperidone. Method. Between November 2001 and May 2002, 16 female outpatients who had taken risperidone for more than 3 months voluntarily reported amenorrhoea. Following each report of amenorrhoea, serum prolactin level was measured and treatment changes were undertaken. The menstrual cycles and clinical mental status of each patient were followed for the next 6 months. For nine of the 16 patients, the dose of risperidone was reduced. For the other seven patients, risperidone was switched to olanzapine or quetiapine. Results. Fourteen of 16 patients had hyperprolactinemia. Two patients who had discontinuation of risperidone recovered from amenorrhoea and three of the risperidone-reduction patients resumed their periods. All subjects in the drug-switch patients recovered. The patients who recovered from amenorrhoea at a reduced dosage of risperidone took ≤3 mg/day. Two patients in the risperidone-reduction group dropped out. Conclusion. Stopping risperidone (without starting any other antipsychotic) or switching to a prolactin-sparing antipsychotic is an effective strategy for resolution of amenorrhoea on risperidone, but that dose reduction is rarely effective either because amenorrhoea continues despite lower dose or because relapse of psychosis appears.

KW - Amenorrhea

KW - Mood disorder

KW - Prolactin

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=14944348035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944348035&partnerID=8YFLogxK

U2 - 10.1080/13651500510014747

DO - 10.1080/13651500510014747

M3 - Article

VL - 9

SP - 29

EP - 34

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 1

ER -